Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnThePath Trial
NCT06973525Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06973525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973525.